Oral Communications 6: Calcium and Bone

ea0073oc6.1 | Oral Communications 6: Calcium and Bone | ECE2021

Osteocalcin actives GPRC6A and calcium-sensing receptor modulating intracellular signaling pathways, cell cycle genes, and apoptosis in human parathyroid tumor cells

Verdelli Chiara , Tavanti Giulia Stefania , Forno Irene , Vaira Valentina , Maggiore Riccardo , Mari Gilberto , Vicentini Leonardo , Ciaramella Paolo Dalino , Lombardi Giovanni , Corbetta Sabrina

Parathyroid glands regulate bone metabolism through PTH, while bone modulates parathyroid function through calcium and FGF23. We tested the hypothesis that the matrix protein osteocalcin (OC), secreted by osteoblasts, may modulate parathyroid function. In human parathyroid cells derived from adenomas (PAds), incubation with g-carboxylated OC (GlaOC) or undercarboxylated OC (GluOC) modulated the intracellular signaling pathways: both GlaOC and GluOC inhibited the basal phosphor...

0 shares

ea0073oc6.2 | Oral Communications 6: Calcium and Bone | ECE2021

AAV liver gene therapy-mediated inhibition of FGF23 signaling as a therapeutic strategy for X-linked hypophosphatemia

Zhukouskaya Volha , Jauze Louisa , Charles Séverine , Leborgne Christian , Hilliquin Stéphane , Sadoine Jérémy , Slimani Lotfi , Baroukh Brigitte , van Wittenberghe Laetitia , Daniele Natalie , Rajas Fabienne , Linglart Agnès , Mingozzi Federico , Chaussain Catherine , Bardet Claire , Ronzitti Giuseppe

Adeno‐associated virus (AAV) gene therapy reached the maturity and a liver-targeting approach is currently used as a replacement treatment for rare hepatic and muscular diseases. X-linked hypophosphatemia (XLH) is a rare disease associated with hyperfunction of fibroblast growth factor 23 (FGF23) in bone and characterized by severe skeletal deformities and short stature. The current medical therapies for XLH requires life-long repeated treatment presenting major limitati...

2 shares

ea0073oc6.3 | Oral Communications 6: Calcium and Bone | ECE2021

Bone material strength index is altered in patients with Cushing’s syndrome even after long-term remission

Schoeb Manuela , Sintenie Paula J.C. , Haalen Femke van , Nijhoff Michiel , de Vries Friso , Biermasz Nienke , Winter Elizabeth M. , Pereira Alberto M , Appelman-Dijkstra Natasha

BackgroundEndogenous Cushings syndrome (CS) is detrimental to bone. The skeletal complications are characterized by decreased bone formation and increased bone resorption, resulting in decreased bone mineral density (BMD) and an increased risk of fractures at time of diagnosis. After remission of the disease, BMD improves towards normal values but fracture rate remains elevated. Therefore, components of bone quality other than BMD, such as bone mat...

0 shares

ea0073oc6.4 | Oral Communications 6: Calcium and Bone | ECE2021

Bisphosphonates after Denosumab withdrawal reduce the vertebral fractures incidence

Grassi Giorgia , Chiodini Iacopo , Palmieri Serena , Cairoli Elisa , Arosio Maura , Eller Vainicher Cristina

ObjectiveSeveral studies showed that patients discontinuing denosumab (Dmab) may experience bone loss and incident vertebral fractures (VFx) due to a rebound bone turnover increase, suggesting the need of anti-resorptive (i.e. bisphosphonate BPs) therapy to mitigate this occurrence. However, the morphometric VFx (morphoVFx) incidence after Dmab discontinuation is unknown and scarce data are available about the BPs effect on BMD changes and Fx risk in thi...

0 shares

ea0073oc6.5 | Oral Communications 6: Calcium and Bone | ECE2021

Safety, tolerability and pharmacodynamics of AZP-3601, a novel long-acting PTH analog, in healthy adults: Data from a randomized, double-blind, placebo-controlled phase 1 study

Allas Soraya , Ovize Michel , Culler Michael D. , Geraul Clarisse , Jeroen van de Wetering , Mannstadt Michael

Hypoparathyroidism is a rare disease characterized by a deficiency in parathyroid hormone (PTH) that results in hypocalcemia and hyperphosphatemia. Current treatment approaches, including high dose oral calcium and active vitamin D, as well as recombinant human PTH (1–84), do not provide adequate or consistent control of either serum calcium or clinical symptoms over a full 24-hour period. AZP-3601 is a novel 36 amino-acid PTH analog that has been designed to potently bi...

1 shares

ea0073oc6.6 | Oral Communications 6: Calcium and Bone | ECE2021

TransCon PTH as a potential hormone replacement therapy for patients with hypoparathyroidism: PaTH forward open-label extension trial week 26 results

Schwarz Peter , Rejnmark Lars , Rubin Mishaela , Vokes Tamara J. , Clarke Bart L. , Ahmed Intekhab , Palermo Andrea , Marcocci Claudio , Pagotto Cristina , Eriksen Erik , Mourya Sanchita , Markova Denka , Pihl Susanne , Shu Aimee , Beckert Michael , Khan Aliya

BackgroundHypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH), resulting in hypocalcemia, hyperphosphatemia, hypercalciuria, and a reduced quality of life (QoL). PTH replacement therapy should restore physiologic levels of PTH and restore downstream physiologic levels of calcitriol, promoting independence from Ca and active vitamin D supplements and normalization of QoL. TransCon PTH is an investigational long-acting p...

0 shares

Endocrine Abstracts

European Congress of Endocrinology 2021